Articles tagged with Fatty Liver Disease
A new scoring system can accurately predict a person's risk of death from non-alcoholic fatty liver disease (NAFLD), the world's most prevalent liver disease. The study found that patients with severe NAFLD had a significantly higher risk of mortality, highlighting the importance of identifying patients at risk.
A new study found that coffee supplementation improved several key markers of NAFLD in mice fed a high-fat diet, including reduced cholesterol and fat accumulation. Coffee also raised levels of Zonulin, which lessens gut permeability, a contributor to liver injury.
Research presented at The International Liver Congress 2016 found that breastfeeding exclusively for six months can reduce the risk of non-alcoholic fatty liver disease (NAFLD) in adolescence by a third. Pre-pregnancy BMI within the normal range also reduces the risk, by half.
Research shows people with type 2 diabetes are more susceptible to non-alcoholic fatty liver disease (NAFLD), a condition characterized by a build-up of fat in liver cells. The study found that hospital admissions and deaths caused by liver disease are likely to rise if cases of type 2 diabetes continue to increase.
Researchers at Newcastle University have developed a DNA-based blood test that can detect liver scarring, also known as fibrosis, in patients with NAFLD. This breakthrough test measures epigenetic markers to stratify patients into mild or severe liver scarring, offering an early diagnosis and potentially improving patient outcomes.
Researchers developed a novel 3D imaging technique that provides accurate detection of advanced fibrosis in liver disease. The technology outperforms current methods, offering improved accuracy and reduced invasiveness.
A new study published in Radiology found that fatty liver disease is independently associated with subclinical heart failure in obese people. The study, which measured hepatic triglyceride content and cardiac function in 714 adults, suggests that dietary interventions may be crucial in preventing or reducing the risk of heart failure.
Researchers suggest GPR119 could treat nonalcoholic fatty liver disease, with administration of its ligand reducing hepatic lipid accumulation in mice. This discovery opens the door to developing new treatments for this increasingly prevalent disease.
Researchers have found a compound that can prevent and reverse fatty liver disease and obesity in mice by targeting the farnesoid X receptor. The compound, Gly-MCA, was tested in obese and diabetic mice fed with a high-fat diet and showed significantly less fat and insulin resistance compared to untreated control groups.
A new study found that obese children and those with Non-Alcoholic Fatty Liver Disease (NAFLD) are not meeting the UK's vitamin and mineral guidelines. They are also significantly off meeting the recommended physical activity levels, with excess weight unlikely to be the only factor in NAFLD development.
Researchers have found that a commonly used Type II diabetes medication can effectively clear fatty liver disease from some patients. After a 48-week trial, 4 out of 10 patients showed significant improvement in non-alcoholic steatohepatitis symptoms.
A genetic variant has been found to increase the risk of fatty liver disease in obese children and adolescents, despite lower total and LDL cholesterol levels. The variant affects the TM6SF2 protein, which regulates fat metabolism in the liver.
A large study of middle-aged Koreans reveals that both sedentary behavior and reduced physical activity contribute to the prevalence of NAFLD. The findings support increasing physical activity and reducing sitting time as crucial in reducing the risk of NAFLD.
Researchers found that normal-weight carriers of the PNPLA3 mutant genotype are at higher risk for non-alcoholic fatty liver disease (NAFLD) and renal function dysfunction. The study suggests this mutation may be used to identify individuals at high-risk for NAFLD, regardless of weight status.
A daily sugar-sweetened beverage habit may increase the risk for non-alcoholic fatty liver disease (NAFLD), researchers found in a study of over 2,600 adults. Consuming more than one sugar-sweetened beverage per day was associated with a higher prevalence of NAFLD.
A large population-based cohort study found that non-alcoholic steatohepatitis (NASH) increases the risk of death by 50% compared to non-alcoholic fatty liver disease (NAFLD). The study also showed that patients with NASH had a higher risk of cardiovascular disease and all-cause mortality over a 14-year period.
Remogliflozin etabonate improves insulin sensitivity and beta cell function, reducing ALT levels and weight in patients with NASH. The investigational drug also exhibits intrinsic anti-oxidant activity, reversing steatohepatitis and oxidative stress.
A study has demonstrated that alginate-enriched bread can inhibit fat digestion and circulatory lipids in patients with non-alcoholic fatty liver disease (NAFLD). The results show a significant reduction of up to 31% in fat digestion, suggesting its potential use as a therapeutic weight management therapy.
A new study published at The International Liver Congress reveals that non-alcoholic fatty liver disease (NAFLD) is associated with the development of coronary artery calcification. In patients without existing CAC, NAFLD significantly accelerated atherosclerosis progression, while in those with existing CAC, it did not affect disease ...
Recent studies confirm that NAFLD worsens heart disease and increases serum levels of cardiovascular risk markers. Additionally, a large population sample found a significant association between psychological distress and liver disease mortality. Meanwhile, inpatient mortality for cirrhosis patients has decreased by 41% in the U.S., at...
A new study published in the Journal of Hepatology shows that exercise, regardless of frequency or intensity, benefits obese and overweight adults with non-alcoholic fatty liver disease (NAFLD). Both aerobic and resistance training-based exercise regimens reduce liver fat and visceral fat. The improvement was independent of weight loss.
Research links non-alcoholic steatohepatitis (NASH) with increased intestinal permeability, suggesting a 'gut-liver axis' role in its development. The study found that liver injury may precede changes in gut permeability, potentially worsening liver disease.
A new oral, controlled-release form of DNP, known as CRMP, reversed fatty liver, insulin resistance, and hyperglycemia in rat models of NAFLD and type 2 diabetes, with no adverse effects. The therapy achieved plasma concentrations that were more than a 100-fold less than the toxic threshold.
Saint Louis University researchers have tested a promising drug candidate that stopped fatty liver disease from progressing to severe liver damage. The drug, SR9238, suppresses lipogenesis and reduces the liver's ability to produce fat.
Non-alcoholic fatty liver disease (NAFLD) affects 25% of adults in the US, with excessive fat building up in liver cells. Researchers at BMC will investigate molecular mechanisms and identify novel treatments for NAFLD using retinoic acid and its nuclear receptor.
Researchers at UC San Diego have developed an MRI-based technique to detect and evaluate nonalcoholic fatty liver disease (NAFLD) in children. The new method estimates liver fat content using a standardized biomarker, PDFF, which correlates well with standard liver biopsy analysis.
A team of researchers found that inhibiting the intestinal farnesoid X receptor with drugs like tempol and antibiotics can prevent nonalcoholic fatty liver disease in mice. This discovery highlights the complex role of gut microbes in human health and potential targets for treating metabolic disorders.
A new study links molecular signaling pathways in the gut, intestinal microbiome, and development of nonalcoholic fatty liver disease (NAFLD). Disruption of the gut microflora prevented NAFLD in mice fed a high-fat diet, suggesting that altering microbial populations may protect against the disease.
A recent study found that obese children with nonalcoholic fatty liver disease (NAFLD) are at a substantial risk for high blood pressure, which can lead to premature cardiovascular disease. The study recommends that blood pressure evaluation and control should be included in the clinical management of children with NAFLD.
Two new treatments for liver diseases are being explored. A probiotic, VSL#3, has been shown to improve liver function and reduce the risk of hospitalization in patients with cirrhosis. Meanwhile, a fatty acid conjugate called Aramchol has been found to significantly reduce liver fat content in patients with nonalcoholic fatty liver di...
Researchers used coronary computed tomography angiography (CCTA) to detect high-risk coronary artery plaque and non-alcoholic fatty liver disease (NAFLD), a condition characterized by abnormal liver function. The study found that NAFLD is associated with high-risk plaque, even after adjusting for traditional risk factors.
A study in mice reveals that dysfunctional ketogenesis promotes fatty liver disease, characterized by excessive hepatic glucose and lipid production. The findings suggest targeting ketogenesis could be a viable approach to treating NAFLD.
A team of scientists led by Prof. Mathias Heikenwälder found that immune cells, particularly CD8+ T cells and NK T cells, play a crucial role in the development of fatty liver disease, non-alcoholic steatohepatitis (NASH), and liver cancer. The study suggests that an existing metabolic imbalance triggers the activation and migration of...
A study found that HIV-infected patients with excess abdominal fat experienced modest reductions in liver fat after receiving tesamorelin, a growth hormone-releasing hormone analog. The treatment also led to significant decreases in abdominal fat accumulation.
A six-month treatment with tesamorelin lowered liver fat modestly but significantly in HIV patients. The drug's impact on glucose metabolism was temporary, and reduced liver inflammation may result from lower fat levels.
A study published in Cell Metabolism reveals that free radical molecules contribute to the development of type 2 diabetes, obesity, and fatty liver disease by inactivating protein tyrosine phosphatases. This inactivation leads to a cascade of events promoting disease progression.
Scientists discovered that blocking GLUT8, a molecule carrying large amounts of fructose into liver cells, prevents fatty livers in mice. The study suggests the liver acts as a sink for processing fructose, potentially harming overall metabolic syndrome.
Research found that snacking on high-fat and high-sugar foods increases intrahepatic triglyceride content and belly fat, but not with larger meal size. The study suggests cutting down on snacking may reduce the prevalence of non-alcoholic fatty liver disease.
Researchers found that lean patients with nonalcoholic fatty liver disease (NAFLD) had a higher overall mortality rate and were more likely to be male and of lower socioeconomic status. They also showed signs of liver inflammation despite having less body fat and lower levels of liver damage.
Bariatric surgery resolves liver inflammation and reverses early-stage liver fibrosis by reducing fat deposits in the liver. The procedure showed significant improvement in nonalcoholic fatty liver disease (NAFLD) in severely obese patients.
A UK study found a genetic variant associated with fatty liver disease severity in pediatric patients. Patients had low vitamin D blood levels throughout the year, and most samples were deficient or insufficient in vitamin D status compared to national health standards.
Two studies confirmed NAFLD as an independent cardiovascular risk factor, increasing the risk of atherosclerosis and carotid plaques. Improvement in liver health through treatment is associated with a reduced risk of developing diabetes.
A meta-analysis published in the European Journal of Clinical Nutrition found that fructose is not responsible for the increase in non-alcoholic fatty liver disease. The study suggests that excess calorie consumption, regardless of source, contributes to the development of the disease. Dr. John Sievenpiper, lead author of the study, em...
Johns Hopkins researchers identified a protein called SCAP that regulates fatty liver disease and diabetes. They found that SCAP's 'chauffeur' role is crucial to the cycle of fat production, and disrupting this process may lead to new treatments.
A research team at CNIO has identified AP-1 proteins as key regulators of fatty liver disease (FLD), a condition that affects up to 30% of adults in Western societies. Increased expression of these proteins can prevent fat accumulation and FLD in mice.
A new study published in Gastroenterology found that high-calorie diets, regardless of sugar type, contribute to the development of nonalcoholic fatty liver disease. The study revealed comparable effects of fructose and glucose on the liver, highlighting calorie intake as a key factor in liver disease progression.
Research published in Hepatology suggests that estrogen has a protective effect against the development of severe liver fibrosis in patients with nonalcoholic steatohepatitis (NASH). The study found that men and post-menopausal women have similar risks of developing severe fibrosis compared to pre-menopausal women.
A new imaging technique, MRE, can accurately detect fibrosis in children with chronic liver disease, including non-alcoholic fatty liver disease. The study showed high accuracy in detecting advanced fibrosis in obese patients, potentially reducing the need for costly and invasive liver biopsies.
Researchers at Duke University Medical Center found that increased caffeine intake may reduce fatty liver in people with non-alcoholic fatty liver disease. Consuming four cups of coffee or tea a day could be beneficial in preventing and protecting against the progression of NAFLD.
Researchers found that weight loss surgery can reverse the symptoms of nonalcoholic fatty liver disease by altering DNA methylation and gene expression. This study provides insight into the mechanisms behind bariatric surgery's benefits beyond weight loss.
Penn State researchers found that cocoa powder supplement reduced inflammation and fatty liver disease in mice fed high-fat diet. The study suggests cocoa's polyphenolic compounds may improve gut barrier function and reduce insulin levels.
A study found that non-alcoholic fatty liver disease (NAFLD) is an independent predictor of early atherosclerosis and 10-year cardiovascular risk. Patients with NAFLD had higher carotid intima-media thickness and Framingham score, indicating increased cardiovascular risk.
Scientists have discovered that dietary medium chain triglycerides (MCT) can prevent the development of nonalcoholic fatty liver disease (NAFLD) in patients with obesity and type II diabetes. MCT substitution for polyunsaturated fat reduces liver fat accumulation and progression of injury, suggesting a potential future therapy.
Researchers have developed a non-invasive test for diagnosing non-alcoholic steatohepatitis (NASH), a more advanced form of NAFLD. The phosphorus magnetic resonance spectroscopy (31P-MRS) technique shows fair diagnostic accuracy for NASH and could improve clinical procedures.
Researchers have identified a gene variant ID associated with non-alcoholic fatty liver disease (NAFLD) diagnosis, including steatosis, steatohepatitis, and fibrosis. The study suggests that screening for this variant could lead to earlier detection and improved management of NAFLD.
Patients with nonalcoholic fatty liver disease (NAFLD) without advanced fibrosis do not have higher mortality risk, according to new research. However, those likely to progress to advanced fibrosis had a 69% increase in mortality compared to those without fibrosis.
Scientists from Scripps Research Institute have developed a synthetic compound that reverses the effects of fatty liver disease by suppressing lipid production in the liver. The compound, SR9238, also significantly lowered total cholesterol levels and reduced markers for liver damage.
Researchers have discovered a gene called BAF60c that plays a crucial role in converting dietary carbohydrates into fat. The study found that mice with the disabled gene did not produce excess fat despite eating a high-carb diet.
Scientists have created a new laboratory opossum model to study nonalcoholic steatohepatitis (NASH), a common liver disease affecting up to 15 million Americans. The study found that high responders carried a mutated ABCB4 gene, leading to cholesterol accumulation in the liver and potential development of NASH.
The guidelines provide evidence-based information for diagnosing and managing non-alcoholic fatty liver disease, which is rapidly becoming the most common cause of cirrhosis in the US. The condition can lead to liver cancer and failure, emphasizing the need for standardized medical care.